.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,399,632

« Back to Dashboard

Claims for Patent: 6,399,632

Title: Method of providing an antihistaminic effect in a hepatically impaired patient
Abstract:The present invention relates to a method of providing an antihistaminic effect in a hepatically impaired patient in need thereof comprising administering to said patient an effective antihistaminic amount of a compound of the formula ##STR1## wherein R.sub.1 is hydrogen or hydroxy; R.sub.2 is hydrogen; or R.sub.1 and R.sub.2 taken together form a second bond between the carbon atoms bearing R.sub.1 and R.sub.2 ; n is an integer of from 1 to 5; R.sub.3 is --COOH or --COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched; each of A and B is hydrogen or hydroxy with the proviso that at least one of A or B is hydrogen; or a pharmaceutically acceptable salt and individual isomers thereof.
Inventor(s): Woodward; James K. (Cincinnati, OH), Okerholm; Richard A. (West Chester, OH), Eller; Mark G. (Overland Park, KS), McNutt; Bruce E. (Olathe, KS)
Assignee: Merrell Pharmaceuticals Inc. (Bridgewater, NJ)
Application Number:09/663,343
Patent Claims: 1. A method of treating a histamine-mediated condition in a patient in whom terfenadine is not metabolized at the normal rate to the terfenadine acid metabolite, while avoiding the concomitant liability of cardiac arrhythmias associated with the administration of terfenadine, said method comprising administering to said patient an effective amount of the compound 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 wherein the amount of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof administered is from about 20 mg to about 800 mg per day.

3. The method of claim 2 wherein the amount of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof administered is from about 40 mg to about 360 mg per day.

4. The method of claim 1 wherein the 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof is administered together with a pharmaceutically acceptable carrier.

5. A method of treating a histamine-mediated condition in a patient in whom terfenadine is not metabolized at the normal rate to the terfenadine acid metabolite, comprising administering to said patient a therapeutically effective amount of the compound 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 wherein the amount of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof administered is from about 20 mg to about 800 mg per day.

7. The method of claim 6 wherein the amount of 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof administered is from about 40 mg to about 360 mg per day.

8. The method of claim 5 wherein the 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt is administered together with a pharmaceutically acceptable carrier.

9. In a method of providing an antihistaminic effect in a patient in whom terfenadine is not metabolized at the normal rate to the terfenadine acid metabolite and who is subject to QT prolongation and/or ventricular tachycardia when using terfenadine, the improvement which comprises administering an effective amount of the compound 4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.al pha.-dimethylbenzeneacetic acid or a pharmaceutically acceptable salt thereof.

10. The method of obtaining an anti-histaminic effect in a human in need of such effect but who has also received a product which inhibits terfenadine metabolism, said method comprising administering to said human, an anti-histaminically effective amount of 4-[-1-hydroxy-4-[4-hydroxy-diphenylmethyl)-1-piperidinyl]butyl]-.alpha.,.a lpha.-dimethyl-benzene acetic acid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc